{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T09:17:40Z","timestamp":1791883060279,"version":"4.3.4"},"reference-count":120,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1053\/j.semnuclmed.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T07:56:09Z","timestamp":1660204569000},"page":"806-815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["FDG PET\/CT for Staging and Restaging Malignant Mesothelioma"],"prefix":"10.1053","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-1094","authenticated-orcid":false,"given":"Egesta","family":"Lopci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5868-3372","authenticated-orcid":false,"given":"Angelo","family":"Castello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8258-5134","authenticated-orcid":false,"given":"Luigi","family":"Mansi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0001","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma epidemiology, carcinogenesis, and pathogenesis","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Treat Options Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0002","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cpet.2011.04.001","article-title":"Multimodality imaging review of malignant pleural mesothelioma diagnosis and staging","volume":"6","author":"Gerbaudo","year":"2011","journal-title":"PET Clin"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0003","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.ro.2013.03.017","article-title":"Malignant pleural mesothelioma: Role of CT, MRI, and PET\/CT in staging evaluation and treatment considerations","volume":"48","author":"Troung","year":"2013","journal-title":"Semin Roentgenol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0004","first-page":"162","article-title":"Latency periods in asbestos-related mesothelioma of the pleura","volume":"6","author":"Bianchi","year":"1997","journal-title":"Eur J Cancer Prev"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.semnuclmed.2021.04.002","article-title":"PET\/CT Variants and pitfalls in lung cancer and mesothelioma","volume":"51","author":"Lopci","year":"2021","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0006","unstructured":"Sauter JL, Bueno R, Dacic S, Gill RR, et al. Diffuse Pleural Mesothelioma. WHO Classification of Tumors Editorial Board. 5th ed. 204-219 Lyon IARC Press, 2021."},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0007","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41379-021-00895-7","article-title":"Pleural mesothelioma classification update and challenges","volume":"35","author":"Dacic","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0008","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s11604-016-0555-1","article-title":"Present and future roles of FDG-PET\/CT imaging in the management of malignant pleural mesothelioma","volume":"34","author":"Kitajima","year":"2016","journal-title":"Jpn J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0009","first-page":"E254","article-title":"Guidelines for the diagnosis and treatment of malignant pleural mesothelioma","volume":"5","author":"van Zandwijk","year":"2013","journal-title":"J Thorac Dis"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fonc.2020.00187","article-title":"Immunotherapy in malignant pleural mesothelioma","volume":"10","author":"de Gooijer","year":"2020","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0011","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0012","first-page":"1","article-title":"Immune checkpoint inhibitor for treatment of mesothelioma","volume":"2","author":"Novak","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0013","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","article-title":"A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group","volume":"108","author":"Rusch","year":"1995","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0014","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC Mesothelioma Staging Project: Proposals for the M descriptors and for revision of the TNM Stage Groupings in the forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0015","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.jtho.2016.09.121","article-title":"The IASLC Mesothelioma Staging Project: Proposals for Re-visions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleu-ral Mesothelioma","volume":"11","author":"Rice","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0016","first-page":"127","article-title":"Clinical staging of malignant pleural mesothelioma: Current perspectives","volume":"8","author":"Bonomi","year":"2017","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0017","doi-asserted-by":"crossref","first-page":"543","DOI":"10.21037\/tlcr.2018.07.05","article-title":"The eighth TNM classification for malignant pleural mesothelioma","volume":"7","author":"Berzenji","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0018","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0019","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.124.3215.269","article-title":"On respiratory impairment in cancer cells","volume":"124","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0020","unstructured":"Warburg O, Posener K, Negelein E. The metabolism of the carcinoma cell. in: Warburg O. The Metabolism of Tumors. Richard R. Smith, Inc, New York, 129-169, 1931"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0021","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0006-291X(90)91263-R","article-title":"Over-expression of facilitative glucose transportergenes in human cancer","volume":"170","author":"Yamamoto","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0022","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0969-8051(94)90162-7","article-title":"FDG uptake tumor proliferation and expression of glycolysis associated genes in animal tumor models","volume":"21","author":"Haberkorn","year":"1994","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0023","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.lungcan.2004.04.016","article-title":"Positron emission tomography in the diagnosis of mesothelioma","volume":"45 S","author":"Haberkorn","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0024","first-page":"239","article-title":"Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma","volume":"46","author":"Kr\u00fcger","year":"2007","journal-title":"Nuklearmedizin"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0025","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/JTO.0b013e3182519d96","article-title":"High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: Supportive evidence to reclassify pleomorphic as nonepithelioid histology","volume":"7","author":"Kadota","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0026","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.ejca.2012.01.016","article-title":"Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma","volume":"48","author":"Kaira","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0027","first-page":"333","article-title":"Clinical implications of 18F-fluorodeoxyglucose positron emission tomography\/computed tomography at delayed phase for diagnosis and prognosis of malig-nant pleural mesothelioma","volume":"27","author":"Abe","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0028","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1055\/s-2008-1039314","article-title":"The role of positron emission tomograohy \/computed tomography in the diagnosis of pleural diseases","volume":"57","author":"Orki","year":"2009","journal-title":"Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0029","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/JTO.0b013e3181c0a7ff","article-title":"Clinical value of fluorodeoxyglucose-positron emission to-mography computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease","volume":"12","author":"Yildrim","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1378\/chest.114.3.713","article-title":"Metabolic Imaging of malig-nant pleural mesothelioma with fluorodeoxyglucose positron emission tomography","volume":"9","author":"Benard","year":"1998","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0031","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1378\/chest.125.2.489","article-title":"Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging","volume":"125","author":"Duysinx","year":"2004","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0032","first-page":"995","article-title":"PET for the evaluation of pleural thickening observed on CT","volume":"45","author":"Kramer","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0033","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MNM.0b013e328310b3ba","article-title":"Dual time point FDG PET for evaluation of malignant pleural mesothelioma","volume":"1","author":"Yamamoto","year":"2009","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0034","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11307-009-0212-5","article-title":"Potential of dual time point FDG-PET imaging in differenti-ating malignant from benign pleural disease","volume":"5","author":"Mavi","year":"2009","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/JTO.0b013e3181cbf465","article-title":"Role of integrated 18-fluorodeoxyglucose positron emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma","volume":"3","author":"Tan","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0036","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3892\/etm.2012.572","article-title":"Clinical utility of 18-fluorodeoxyglucose positron emission tomography\/computed tomography in malignant pleural mesothelioma","volume":"4","author":"Terada","year":"2012","journal-title":"Exp Ther Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0037","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/RLU.0b013e31815c5004","article-title":"Systemic disseminated tuberculosis mimicking malignancy on F-18 FDG PET-CT","volume":"33","author":"Li","year":"2008","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0038","article-title":"Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET\/CT scan in patients with malignant pleural mesothelioma","volume":"15","author":"Lim","year":"2020","journal-title":"PLoS One"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0039","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/MNM.0000000000000649","article-title":"The role of 18F-FDG-PET\/ceCT in peritoneal mesothelioma","volume":"38","author":"Dubreuil","year":"2017","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0040","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1378\/chest.14-0820","article-title":"Accuracy of fluorodeoxyglu-cose-PET imaging for differentiating benign from malignant pleural effusions: A meta-analysis","volume":"147","author":"Porcel","year":"2015","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0041","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/icvts\/ivz303","article-title":"18F-fluorodeoxyglycose positron emission tomography in malignant pleural mesothelioma: Diagnostic and prognostic performance and its correlation to pathological results","volume":"30","author":"Lococo","year":"2020","journal-title":"Interact cardiovasc Thorac Surg"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0042","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2214\/ajr.154.3.2106209","article-title":"CT in differential diagnosis of diffuse pleural disease","volume":"154","author":"Leung","year":"1990","journal-title":"Am J Roentgenol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0043","first-page":"149","article-title":"Role of 18F-FDG PET for evaluating malignant pleural me-sothelioma","volume":"4","author":"Nanni","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0044","first-page":"111","article-title":"Additional value of hybrid PET\/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural meso-thelioma","volume":"8","author":"Ambrosini","year":"2005","journal-title":"Nucl Med Rev"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0045","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3816\/CLC.2009.n.033","article-title":"Utility of integrated computed tomography \u2013 Positron emission tomography for selection of operable malignant pleural mesothelioma","volume":"10","author":"Wilcox","year":"2009","journal-title":"Clin Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0046","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ejcts.2008.07.050","article-title":"Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy","volume":"34","author":"Sorensen","year":"2008","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0047","first-page":"1144","article-title":"Assessment of malignant pleural mesothelioma with 18FFDG Dual Head Gamma-Camera coincidence imaging: comparison with histopathology","volume":"9","author":"Gerbaudo","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0048","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/RLI.0b013e3181817b3d","article-title":"Computed tomography, positron emission tomography-computed tomography and magnetic resonance imaging for staging of limited pleural mesothelioma","volume":"10","author":"Plathow","year":"2008","journal-title":"Invest Radiol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0049","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jtcvs.2004.10.034","article-title":"Integrated computed-tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications","volume":"6","author":"Erasmus","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0050","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s00259-010-1704-x","article-title":"FDG PET\/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival","volume":"38","author":"Gerbaudo","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0051","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.clinimag.2013.06.009","article-title":"18F-FDG PET\/CT in suspected recurrences of epithelial malignant pleural mesothelioma in asbestos-fibers-exposed patients (comparison to stand-and diagnostic follow-up)","volume":"37","author":"Niccoli-Asabella","year":"2013","journal-title":"Clin Imaging"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0052","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/RLU.0b013e3181bece11","article-title":"F-18 FDG PET\/CT characterization of talc pleurodesis-induced pleural changes over time: A retrospective study","volume":"34","author":"Nguyen","year":"2009","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0053","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/686153","article-title":"Persistent inflammation in pulmonary granuloma 48 years after talcage pleurodesis, detected by FDG-PET\/CT","volume":"2012","author":"Fanggiday","year":"2012","journal-title":"Case Rep Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0054","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000356752","article-title":"Positive FDG-PET\/CT of the pleura twenty years after talc pleurodesis: Three cases of benign talcoma","volume":"87","author":"Vandemoortele","year":"2014","journal-title":"Respiration"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0055","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1378\/chest.125.6.2356","article-title":"Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis","volume":"125","author":"Kwek","year":"2004","journal-title":"Chest"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0056","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.lungcan.2007.05.015","article-title":"False positive 18F-FDG-PET\/CT in a patient after talc pleurodesis","volume":"58","author":"Ahmadzadehfar","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0057","first-page":"2009","article-title":"Pleural FDG uptake more than a decade after talc pleurodesis","volume":"650864","author":"Peek","year":"2009","journal-title":"Case Rep Med,"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153660","article-title":"Histology of the pleural rind at [18F]FDG PET\/CT hot and cold spots in mesothelioma patients after talc pleurodesis and neoadjuvant chemotherapy","volume":"228","author":"Soltermann","year":"2021","journal-title":"Pathol Res Pract"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0059","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s002680020021","article-title":"Treatment of malignant mesothelioma","volume":"25","author":"Jaklitsch","year":"2001","journal-title":"World J Surg"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0060","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","article-title":"Malignant pleural mesothelioma","volume":"27","author":"Tsao","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0061","first-page":"182","article-title":"Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma","volume":"3","author":"Zhang","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0062","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0003-4975(96)01228-3","article-title":"Patterns of failure after trimodality therapy for malignant pleural mesothelioma","volume":"63","author":"Baldini","year":"1997","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0063","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.thorsurg.2004.06.006","article-title":"Patterns of failure following surgical resection for malignant pleural mesothelioma","volume":"14","author":"J\u00e4nne","year":"2004","journal-title":"Thorac Surg Clin"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0064","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0065","doi-asserted-by":"crossref","DOI":"10.1053\/j.semnuclmed.2022.04.008","article-title":"A Role for PET\/CT in response assessment of malignant pleural mesothelioma","author":"Sandach","year":"2022","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0066","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00259-014-2960-y","article-title":"Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma","volume":"42","author":"Lopci","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0067","series-title":"Atlas of Response to Immunotherapy","article-title":"Malignant pleural mesothelioma: 18F-FDG PET\/CT for response assessment of malignant pleural mesothelioma following immunotherapy","author":"Lopci","year":"2020"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0068","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2006.06.8999","article-title":"Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F] fluorodeoxyglucose","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0069","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.107.042333","article-title":"Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans","volume":"48","author":"Francis","year":"2007","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0070","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.lungcan.2009.04.015","article-title":"Combined FDG-PET\/CT in response evaluation of malignant pleural mesothelioma","volume":"67","author":"Veit-Haibach","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0071","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1245\/s10434-010-1107-z","article-title":"Volume-based parameter of 18F-FDG PET\/CT in malignant pleural mesothelioma: Prediction of therapeutic response and prognostic implications","volume":"17","author":"Lee","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0072","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7150\/jca.2586","article-title":"FDG PET\/CT response evaluation in malignant pleural mesothelioma patients treated with talc pleurodesis and chemotherapy","volume":"3","author":"Genestreti","year":"2012","journal-title":"J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0073","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/j.ejrad.2010.11.006","article-title":"Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): Value of 18F-FDG PET\/CT","volume":"81","author":"Schaefer","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0074","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00259-013-2561-1","article-title":"The association of 18F-FDG PET\/CT parameters with survival in malignant pleural mesothelioma","volume":"41","author":"Klabatsa","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0075","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"10.1053\/j.semnuclmed.2022.07.005_bib0076","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0077","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/MNM.0000000000001223","volume":"41","author":"Kitajima","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0078","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2967\/jnumed.120.245803","article-title":"Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma","volume":"62","author":"Ferdinandus","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0079","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/cam4.1182","article-title":"Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy","volume":"6","author":"Zucali","year":"2017","journal-title":"Cancer Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0080","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","article-title":"Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [18F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0","volume":"49","author":"Lopci","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0081","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13550-020-00669-3","article-title":"FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients","volume":"10","author":"Pavic","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0082","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"L\u00f3pez-R\u00edos","year":"2006","journal-title":"Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0083","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/sj.onc.1209809","article-title":"Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors","volume":"26","author":"Borczuk","year":"2007","journal-title":"Oncogene"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0084","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1245\/s10434-013-3358-y","article-title":"Malignant peritoneal mesothelioma: Prognostic factors and oncologic outcome analysis","volume":"21","author":"Magge","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0085","doi-asserted-by":"crossref","first-page":"839","DOI":"10.21873\/anticanres.13183","article-title":"Malignant peritoneal mesothelioma: Treatment options and survival","volume":"39","author":"Salo","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0086","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s10434-999-0582-6","article-title":"Treatment of primary peritoneal mesothelioma by Continuous Hyperthermic Peritoneal Perfusion (CHPP)","volume":"6","author":"Park","year":"1999","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0087","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: Multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"JCO"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0088","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1245\/s10434-018-6337-5","article-title":"Current management and future opportunities for peritoneal metastases: Peritoneal mesothelioma","volume":"25","author":"Alexander","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0089","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/JCO.2020.38.15_suppl.9013","article-title":"A phase II trial of atezolizumab and bevacizumab in patients with relapsed\/refractory and unresectable malignant peritoneal mesothelioma","volume":"38 (suppl)","author":"Raghav","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0090","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.19934","article-title":"Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma","volume":"4","author":"Raghav","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0091","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s00261-022-03464-x","article-title":"The role of imaging in diagnosis and management of malignant peritoneal mesothelioma: A systematic review","volume":"47","author":"Carlson","year":"2022","journal-title":"Abdom Radiol (NY)"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0092","first-page":"1067","article-title":"Computed tomographic features of malignant peritoneal mesothelioma","volume":"36","author":"Kato","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0093","first-page":"54","article-title":"Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma","volume":"60","author":"Dom\u00e8nech-Vilardell","year":"2016","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0094","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0899-7071(02)00424-2","article-title":"Pitfalls in diagnosis of early stage malignant peritoneal mesothelioma: A case report","volume":"26","author":"Lee","year":"2002","journal-title":"Clinical Imaging"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MNM.0000000000000613","article-title":"18F-FDG-PET\/CT of peritoneal tumors: A pictorial essay","volume":"38","author":"Dubreuil","year":"2017","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0096","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1245\/s10434-009-0387-7","article-title":"18F-FDG-PET\/CT to select patients with peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"16","author":"Pfannenberg","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0097","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00261-012-9881-7","article-title":"Preoperative assessment of peritoneal carcinomatosis: Intraindividual comparison of 18F-FDG PET\/CT and MRI","volume":"38","author":"Klumpp","year":"2013","journal-title":"Abdom Imaging"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0098","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0022-5223(03)00207-1","article-title":"Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma","volume":"126","author":"Flores","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0099","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1078-0432.CCR-09-2313","article-title":"A Novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging and clinical parameters","volume":"16","author":"Nowak","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0100","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/01.rlu.0000089522.86184.49","article-title":"Talc pleurodesis mimics pleural metastases: Differentiation with positron emission tomography\/computed tomography","volume":"28","author":"Weiss","year":"2003","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0101","first-page":"432","article-title":"Radiolabeled amino acids: Basic aspects and clinical applications in oncology","volume":"42","author":"Jager","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0102","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1056\/NEJMc071823","article-title":"11C-labeled methionine and evaluation of malignant pleural mesothelioma","volume":"357","author":"Ceresoli","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0103","first-page":"4075","article-title":"L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma","volume":"31","author":"Kaira","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0104","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/MNM.0000000000001078","article-title":"In-vivo imaging of methionine metabolism in patients with suspected malignant pleural mesothelioma","volume":"40","author":"Lopci","year":"2019","journal-title":"Nucl Med Commun"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0105","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/(SICI)1099-1492(199911)12:7<413::AID-NBM587>3.0.CO;2-U","article-title":"Tumour phospholipid metabolism","volume":"12","author":"Podo","year":"1999","journal-title":"NMR Biomed"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0106","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrc3162","article-title":"Choline metabolism in malignant transformation","volume":"11","author":"Glunde","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0107","first-page":"e3654","article-title":"Fluorodeoxyglucose versus choline positron emission tomography\/computed tomography response evaluation in two malignant pleural mesothelioma patients treated with talc pleurodesis and neoadjuvant chemotherapy","volume":"10","author":"Kitajima","year":"2018","journal-title":"Cureus"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0108","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1097\/RLU.0000000000002416","article-title":"Pleural mesothelioma detects by 18F-Choline PET\/CT in a patient with biochemical recurrence of prostate cancer","volume":"44","author":"Rensi","year":"2019","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0109","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/268172","article-title":"A novel PET imaging using Cu-labeled monoclonal antibody against mesothelin commonly expressed on cancer cells","author":"Kobayashi","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0110","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Modern Pathol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0111","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1016\/j.bmcl.2017.05.077","article-title":"Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma","volume":"27","author":"Huang","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"issue":"Pt 2","key":"10.1053\/j.semnuclmed.2022.07.005_bib0112","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/bj3420249","article-title":"Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions","volume":"342","author":"D'Amours","year":"1999","journal-title":"Biochem J"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0113","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nature Rev Cancer"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0114","doi-asserted-by":"crossref","first-page":"96732","DOI":"10.18632\/oncotarget.18235","article-title":"Targeting CXCR4 with [68Ga]Pentixafor: A suitable theranostic approach in pleural mesothelioma?","volume":"8","author":"Lapa","year":"2017","journal-title":"Oncotarget"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0115","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1309\/LN2075V7C8K31CH8","article-title":"Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells","volume":"127","author":"Davidson","year":"2007","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0116","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","article-title":"A review on CXCR4\/CXCL12 axis in oncology: No place to hide","volume":"49","author":"Domanska","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0117","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/cmdc.201100320","article-title":"PET imaging of CXCR4 receptors in cancer by a new optimized ligand","volume":"6","author":"Demmer","year":"2011","journal-title":"Chem Med Chem"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0118","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2967\/jnumed.111.098798","article-title":"PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent","volume":"52","author":"Gourni","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0119","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET \/CT: Biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2022.07.005_bib0120","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/RLU.0000000000003858","article-title":"68Ga-FAPI-04 PET\/CT versus 18F-FDG PET\/CT in malignant peritoneal mesothelioma","volume":"47","author":"G\u00fcndo\u011fan","year":"2022","journal-title":"Clin Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129982200068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000129982200068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T08:58:53Z","timestamp":1762073933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000129982200068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":120,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S000129982200068X"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.07.005","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FDG PET\/CT for Staging and Restaging Malignant Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}